Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P33947
UPID:
ERD22_HUMAN
Alternative names:
ERD2-like protein 1; KDEL endoplasmic reticulum protein retention receptor 2
Alternative UPACC:
P33947; A4D2P4; Q6IPC5; Q96E30
Background:
ER lumen protein-retaining receptor 2, also known as ERD2-like protein 1 or KDEL endoplasmic reticulum protein retention receptor 2, plays a crucial role in cellular function. It binds the K-D-E-L sequence motif in endoplasmic reticulum resident proteins, ensuring their retention or recycling back from the Golgi apparatus. This process is pH-dependent, with optimal activity at pH 5-5.4.
Therapeutic significance:
Osteogenesis imperfecta 21, a connective tissue disorder characterized by bone fragility, is linked to mutations affecting this protein. Understanding the role of ER lumen protein-retaining receptor 2 could open doors to potential therapeutic strategies for this and related conditions.